Search Results
Apr 15, 2026, 09:00 ET IBRX Investor Alert: ImmunityBio Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Violated FDA Drug Rules: Levi & Korsinsky
Levi & Korsinsky, LLP notifies investors in ImmunityBio, Inc. (NASDAQ: IBRX) that a class action lawsuit has been filed on behalf of shareholders who purchased securities between January 19, 2026 and March 24, 2026. IBRX shares fell $1.98 per share, or 21%, after the FDA determined that the Company's
More news about: Levi & Korsinsky, LLP
Apr 14, 2026, 17:26 ET ImmunityBio, Inc. (IBRX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
IBRX).
More news about: Glancy Prongay Wolke & Rotter LLP
Apr 14, 2026, 12:09 ET CLASS ACTION NOTICE: Berger Montague Advises ImmunityBio, Inc. (NASDAQ: IBRX) Investors to Inquire About a Securities Fraud Class Action
Berger Montague PC announces a class action lawsuit against ImmunityBio, Inc. (NASDAQ: IBRX) ("ImmunityBio" or the "Company") on behalf of investors who purchased or acquired ImmunityBio shares during the period from January 19, 2026
More news about: Berger Montague
Apr 13, 2026, 19:31 ET ImmunityBio, Inc. (IBRX) Facing Securities Class Action Amid FDA Warning Regarding Unsupported Cancer Treatment Claims, $2 Billion Market Capitalization Wiped Out -- Hagens Berman
www.hbsslaw.com/investor-fraud/ibrxContact the Firm Now: [email protected] 844-916-0895ImmunityBio, Inc. (IBRX) Securities Class
More news about: Hagens Berman Sobol Shapiro LLP
Apr 11, 2026, 21:30 ET IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit First Filed by The Rosen Law Firm
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19, 2026 and March 24, 2026, both dates inclusive (the "Class Period"), of the important May 26, 2026 lead plaintiff deadline in the
More news about: THE ROSEN LAW FIRM, P. A.
Apr 10, 2026, 22:00 ET ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
Who is Involved: ImmunityBio, Inc. (NasdaqGS: IBRX) investors that purchased between January 19, 2026 and March 24, 2025When to Act: Deadline to file Lead Plaintiff applications is May 26, 2026Basis: ImmunityBio shares fell on FDA warning letter
More news about: Kahn Swick & Foti, LLC
Apr 10, 2026, 16:03 ET ImmunityBio, Inc. (IBRX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
IBRX). IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN IMMUNITYBIO, INC. (IBRX), CONTACT THE LAW OFFICES OF HOWARD G. SMITH BEFORE MAY 26, 2026 (LEAD PLAINTIFF DEADLINE) TO
More news about: Law Offices of Howard G. Smith
Apr 10, 2026, 10:20 ET IBRX UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026
LLP, a leading national securities law firm, is investigating potential claims against ImmunityBio, Inc. ("ImmunityBio" or the "Company") (NASDAQ: IBRX) and reminds investors of the May 26, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed
More news about: Faruqi & Faruqi, LLP
Apr 09, 2026, 17:45 ET ImmunityBio, Inc. (IBRX) Facing Securities Class Action Amid FDA Warning Regarding Unsupported Cancer Treatment Claims, $2 Billion Market Capitalization Wiped Out -- Hagens Berman
www.hbsslaw.com/investor-fraud/ibrxContact the Firm Now: [email protected], Inc. (IBRX) Securities Class Action: ImmunityBio
More news about: Hagens Berman Sobol Shapiro LLP
Apr 09, 2026, 16:45 ET ImmunityBio, Inc. (IBRX) Investors: May 26, 2026, Filing Deadline in Securities Fraud Class Action - Contact Kessler Topaz Meltzer & Check, LLP
Did you buy IBRX securities between January 19, 2026, and March 24, 2026?Affected IBRX Investor SummaryWho: ImmunityBio, Inc. (
More news about: Kessler Topaz Meltzer & Check, LLP
Apr 09, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ImmunityBio, Inc. Of Class Action Lawsuit and Upcoming Deadlines - IBRX
multimedia:https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-reminds-investors-with-losses-on-their-investment-in-immunitybio-inc-of-class-action-lawsuit-and-upcoming-deadlines--ibrx-302737845.htmlSOURCE
More news about: Pomerantz LLP
Apr 08, 2026, 12:00 ET ImmunityBio, Inc. (IBRX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
IBRX) have opportunity to lead the securities fraud class action lawsuit.
More news about: The Law Offices of Frank R. Cruz, Los Angeles
Apr 08, 2026, 11:12 ET INVESTOR DEADLINE: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead the ImmunityBio Class Action Lawsuit
Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of ImmunityBio, Inc. (NASDAQ: IBRX) publicly traded securities between January 19, 2026 and March 24, 2026, all dates inclusive (the "Class Period"), have until May 26, 2026 to seek appointment
More news about: Robbins Geller Rudman & Dowd LLP
Apr 07, 2026, 12:10 ET IBRX SHAREHOLDER UPDATE: ImmunityBio (IBRX) Sued After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- Hagens Berman
www.hbsslaw.com/investor-fraud/ibrxContact the Firm Now: [email protected] 844-916-0895ImmunityBio, Inc. (IBRX) Securities Class
More news about: Hagens Berman Sobol Shapiro LLP
Apr 07, 2026, 09:00 ET IBRX Shareholder Alert: ImmunityBio, Inc. Securities Class Action Lawsuit Investors With Losses May Join -- The Gross Law Firm
April 7, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of ImmunityBio, Inc. (NASDAQ: IBRX).
More news about: The Gross Law Firm
Apr 07, 2026, 01:57 ET IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit First Filed By the Firm
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19, 2026 and March 24, 2026, both dates inclusive (the "Class Period"), of the important May 26, 2026 lead plaintiff deadline in the
More news about: THE ROSEN LAW FIRM, P. A.
Apr 06, 2026, 03:55 ET ImmunityBio, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - IBRX
IBRX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of IBRX during the class period listed are encouraged
More news about: DJS Law Group LLP
Apr 06, 2026, 03:49 ET IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm
IBRX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange
More news about: The Schall Law Firm
Apr 04, 2026, 07:33 ET IBRX SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026
LLP, a leading national securities law firm, is investigating potential claims against ImmunityBio, Inc. ("ImmunityBio" or the "Company") (NASDAQ: IBRX) and reminds investors of the May 26, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed
More news about: Faruqi & Faruqi, LLP
Apr 03, 2026, 23:14 ET INVESTOR NOTICE: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead the ImmunityBio Class Action Lawsuit
Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of ImmunityBio, Inc. (NASDAQ: IBRX) publicly traded securities between January 19, 2026 and March 24, 2026, inclusive (the "Class Period"), have until May 26, 2026 to seek appointment
More news about: Robbins Geller Rudman & Dowd LLP
Apr 03, 2026, 22:15 ET IBRX INVESTOR ALERT: ImmunityBio (IBRX) Sued After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- Hagens Berman
www.hbsslaw.com/investor-fraud/ibrxContact the Firm Now: [email protected] 844-916-0895ImmunityBio, Inc. (IBRX) Securities Class
More news about: Hagens Berman Sobol Shapiro LLP
Apr 03, 2026, 22:03 ET ImmunityBio Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against ImmunityBio, Inc. - IBRX
ImmunityBio, Inc. (NasdaqGS: IBRX) ("ImmunityBio" or the "Company"), if they purchased or otherwise acquired the Company's securities between January 19, 2026 and March 24, 2026, inclusive
More news about: ClaimsFiler
Apr 03, 2026, 09:38 ET ImmunityBio, Inc. (IBRX) Class Action Lawsuit: Investors Face May 26, 2026, Deadline
Did you buy IBRX securities between January 19, 2026, and March 24, 2026?Affected IBRX Investor SummaryWho: ImmunityBio, Inc. (
More news about: Kessler Topaz Meltzer & Check, LLP
Apr 03, 2026, 01:48 ET ImmunityBio, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - IBRX
IBRX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of IBRX during the class period listed are encouraged
More news about: DJS Law Group LLP
Apr 03, 2026, 01:06 ET IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm
IBRX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange
More news about: The Schall Law Firm